Sense-antisense gene-pairs in breast cancer and associated pathological pathways
暂无分享,去创建一个
Vladimir A. Kuznetsov | Anna V. Ivshina | Efthymios Motakis | Aliaksandr A. Yarmishyn | Surya Pavan Yenamandra | Ghim Siong Ow | V. Kuznetsov | S. P. Yenamandra | A. Yarmishyn | O. Grinchuk | Efthymios Motakis | G. Ow | Piroon Jenjaroenpun | Zhiqun Tang | A. Ivshina | Piroon Jenjaroenpun | Oleg V. Grinchuk | Zhiqun Tang | P. Jenjaroenpun
[1] P. Shannon,et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. , 2003, Genome research.
[2] J. Kutok,et al. BAL1 and BBAP Are Regulated by a Gamma Interferon-Responsive Bidirectional Promoter and Are Overexpressed in Diffuse Large B-Cell Lymphomas with a Prominent Inflammatory Infiltrate , 2006, Molecular and Cellular Biology.
[3] Sunghoon Kim,et al. Lentiviral vector-mediated shRNA against AIMP2-DX2 suppresses lung cancer cell growth through blocking glucose uptake , 2012, Molecules and cells.
[4] Joshy George,et al. Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. , 2006, Cancer research.
[5] Minoru Yoshida,et al. Splicing in oncogenesis and tumor suppression , 2012, Cancer science.
[6] Yuan Yuan,et al. Inhibition of breast and brain cancer cell growth by BCCIPα, an evolutionarily conserved nuclear protein that interacts with BRCA2 , 2001, Oncogene.
[7] W. Cai,et al. Comparative RNA-seq analysis reveals potential mechanisms mediating the conversion to androgen independence in an LNCaP progression cell model. , 2014, Cancer letters.
[8] T. Yokota,et al. GABPalpha regulates Oct-3/4 expression in mouse embryonic stem cells. , 2007, Biochemical and biophysical research communications.
[9] G. Nahler. disease free survival (DFS) , 2009 .
[10] Vladimir A Kuznetsov,et al. In the pursuit of complexity: systems medicine in cancer biology. , 2006, Cancer cell.
[11] Barnett,et al. Supplementary References , 2022 .
[12] Shridar Ganesan,et al. X chromosomal abnormalities in basal-like human breast cancer. , 2006, Cancer cell.
[13] L. Holmberg,et al. Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts , 2005, Breast Cancer Research.
[14] Jie Xu,et al. Aurora kinase A inhibition-induced autophagy triggers drug resistance in breast cancer cells , 2012, Autophagy.
[15] Y. Assaraf,et al. Pre-mRNA splicing in cancer: the relevance in oncogenesis, treatment and drug resistance , 2015, Expert opinion on drug metabolism & toxicology.
[16] R. Medema,et al. Aurora-A and hBora join the game of Polo. , 2009, Cancer research.
[17] Mårten Fryknäs,et al. Inhibition of proteasome deubiquitinating activity as a new cancer therapy , 2011, Nature Medicine.
[18] D. Hoyle,et al. Identification of secondary targets of N-containing bisphosphonates in mammalian cells via parallel competition analysis of the barcoded yeast deletion collection , 2009, Genome Biology.
[19] N. Kohno,et al. Functional evidence for Eme1 as a marker of cisplatin resistance , 2009, International journal of cancer.
[20] Vladimir A Kuznetsov,et al. Meta‐analysis of transcriptome reveals let‐7b as an unfavorable prognostic biomarker and predicts molecular and clinical subclasses in high‐grade serous ovarian carcinoma , 2014, International journal of cancer.
[21] M. Marra,et al. Extensive relationship between antisense transcription and alternative splicing in the human genome. , 2011, Genome research.
[22] V. Kuznetsov,et al. Data-driven approach to predict survival of cancer patients: estimation of microarray genes' prediction significance by Cox proportional hazard regression model. , 2009, IEEE engineering in medicine and biology magazine : the quarterly magazine of the Engineering in Medicine & Biology Society.
[23] J. Cadiñanos,et al. Novel germline SDHD deletion associated with an unusual sympathetic head and neck paraganglioma , 2011, Head & neck.
[24] S. Scherer,et al. Subgroup-specific alternative splicing in medulloblastoma , 2012, Acta Neuropathologica.
[25] H. Dressman,et al. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer. , 2008, JAMA.
[26] Derek Y. Chiang,et al. The landscape of somatic copy-number alteration across human cancers , 2010, Nature.
[27] Charlotta Lindvall,et al. Cdc7-Dbf4 kinase overexpression in multiple cancers and tumor cell lines is correlated with p53 inactivation. , 2008, Neoplasia.
[28] B. Teh,et al. DOK4/IRS‐5 expression is altered in clear cell renal cell carcinoma , 2007, International journal of cancer.
[29] M. Kitagawa,et al. Cell cycle-dependent regulation of the Skp2 promoter by GA-binding protein. , 2003, Cancer research.
[30] Raja Jothi,et al. GABP controls a critical transcription regulatory module that is essential for maintenance and differentiation of hematopoietic stem/progenitor cells. , 2011, Blood.
[31] L. Giudice,et al. Perivascular Human Endometrial Mesenchymal Stem Cells Express Pathways Relevant to Self-Renewal, Lineage Specification, and Functional Phenotype1 , 2012, Biology of reproduction.
[32] K. Sträßer,et al. Splicing and beyond: the many faces of the Prp19 complex. , 2013, Biochimica et biophysica acta.
[33] A. Frigessi,et al. Principles and methods of integrative genomic analyses in cancer , 2014, Nature Reviews Cancer.
[34] Paloma H. Giangrande,et al. Current progress on aptamer-targeted oligonucleotide therapeutics. , 2013, Therapeutic delivery.
[35] Lin Ji,et al. Tumor suppressor 101F6 and ascorbate synergistically and selectively inhibit non-small cell lung cancer growth by caspase-independent apoptosis and autophagy. , 2007, Cancer research.
[36] Victoria Kristina Perry,et al. Gene expression abnormalities in histologically normal breast epithelium of breast cancer patients , 2007, International journal of cancer.
[37] L. Steinmetz,et al. Gene regulation by antisense transcription , 2013, Nature Reviews Genetics.
[38] Jeffrey T. Leek,et al. Gene expression EDGE : extraction and analysis of differential gene expression , 2006 .
[39] Cheng Li,et al. Adjusting batch effects in microarray expression data using empirical Bayes methods. , 2007, Biostatistics.
[40] M. Moore,et al. The Biflavonoid Isoginkgetin Is a General Inhibitor of Pre-mRNA Splicing , 2008, Journal of Biological Chemistry.
[41] S. Mott,et al. The Ets transcription factor GABP is required for cell-cycle progression , 2007, Nature Cell Biology.
[42] S. Michiels,et al. Exonic expression profiling of breast cancer and benign lesions: a retrospective analysis. , 2009, The Lancet. Oncology.
[43] Graziano Pesole,et al. Pscan: finding over-represented transcription factor binding site motifs in sequences from co-regulated or co-expressed genes , 2009, Nucleic Acids Res..
[44] O. Khorkova,et al. Natural antisense transcripts as therapeutic targets. , 2013, Drug discovery today. Therapeutic strategies.
[45] M. Moore,et al. Meayamycin inhibits pre–messenger RNA splicing and exhibits picomolar activity against multidrug-resistant cells , 2009, Molecular Cancer Therapeutics.
[46] H. P. Kang,et al. Cancer-Associated Splicing Variant of Tumor Suppressor AIMP2/p38: Pathological Implication in Tumorigenesis , 2011, PLoS genetics.
[47] C. Will,et al. The Spliceosome: Design Principles of a Dynamic RNP Machine , 2009, Cell.
[48] 神代 理史. The ubiquitin ligase CHIP acts as an upstream regulator of oncogenic pathways , 2009 .
[49] A. Chalk,et al. RNAi Screen Indicates Widespread Biological Function for Human Natural Antisense Transcripts , 2010, PloS one.
[50] Mieke Timmermans,et al. Which cyclin E prevails as prognostic marker for breast cancer? Results from a retrospective study involving 635 lymph node-negative breast cancer patients. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.
[51] J. Pietenpol,et al. Identification and use of biomarkers in treatment strategies for triple‐negative breast cancer subtypes , 2014, The Journal of pathology.
[52] M Endo,et al. Isolation of murine and human homologues of the fission-yeast dis3+ gene encoding a mitotic-control protein and its overexpression in cancer cells with progressive phenotype. , 1997, Cancer research.
[53] J. Bergh,et al. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[54] Krishna R. Kalari,et al. Radiation pharmacogenomics: a genome-wide association approach to identify radiation response biomarkers using human lymphoblastoid cell lines. , 2010, Genome research.
[55] W. Shoji,et al. NCYM promotes calpain-mediated Myc-nick production in human MYCN-amplified neuroblastoma cells. , 2015, Biochemical and biophysical research communications.
[56] David Haussler,et al. The UCSC Genome Browser database: 2014 update , 2013, Nucleic Acids Res..
[57] M. Piccart,et al. Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study , 2008, British Journal of Cancer.
[58] A. Gutierrez-Hartmann,et al. Molecular mechanisms of ETS transcription factor-mediated tumorigenesis , 2013, Critical reviews in biochemistry and molecular biology.
[59] Yanqing Ding,et al. Protein and mRNA Characterization in Human Colorectal Carcinoma Cell Lines with Different Metastatic Potentials , 2007, Cancer investigation.
[60] Xing-Hua Liao,et al. Estrogen receptor α mediates proliferation of breast cancer MCF–7 cells via a p21/PCNA/E2F1‐dependent pathway , 2014, The FEBS journal.
[61] J. Smyth,et al. Altered ErbB receptor signaling and gene expression in cisplatin-resistant ovarian cancer. , 2005, Cancer research.
[62] Beatriz Carvalho,et al. Gene‐dosage dependent overexpression at the 13q amplicon identifies DIS3 as candidate oncogene in colorectal cancer progression , 2014, Genes, chromosomes & cancer.
[63] T. Livache,et al. TOX4 and its binding partners recognize DNA adducts generated by platinum anticancer drugs. , 2011, Archives of biochemistry and biophysics.
[64] L. Pasqualucci,et al. Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. , 2011, Blood.
[65] A. Syvänen,et al. Digital gene expression profiling of primary acute lymphoblastic leukemia cells , 2011, Leukemia.
[66] Jian Liu,et al. Niemann-Pick C1 Protein Facilitates the Efflux of the Anticancer Drug Daunorubicin from Cells According to a Novel Vesicle-Mediated Pathway , 2006, Journal of Pharmacology and Experimental Therapeutics.
[67] J. Fondell,et al. Regulation of Aurora-A Kinase Gene Expression via GABP Recruitment of TRAP220/MED1* , 2006, Journal of Biological Chemistry.
[68] N. Czaicki,et al. Total syntheses, fragmentation studies, and antitumor/antiproliferative activities of FR901464 and its low picomolar analogue. , 2007, Journal of the American Chemical Society.
[69] J. Schellens,et al. Tubulin, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non small-cell lung cancer receiving first-line platinum-gemcitabine chemotherapy. , 2011, Lung cancer.
[70] F. André,et al. Targeting the deregulated spliceosome core machinery in cancer cells triggers mTOR blockade and autophagy. , 2013, Cancer research.
[71] D. Watson,et al. CaSm antisense gene therapy: a novel approach for the treatment of pancreatic cancer. , 2003, Anticancer research.
[72] D. Berdnik,et al. Mitotic activation of the kinase Aurora-A requires its binding partner Bora. , 2006, Developmental cell.
[73] Gianluca Bontempi,et al. Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen , 2008, BMC Genomics.
[74] Sang Kyun Sohn,et al. MGMT −535G>T polymorphism is associated with prognosis for patients with metastatic colorectal cancer treated with oxaliplatin-based chemotherapy , 2010, Journal of Cancer Research and Clinical Oncology.
[75] P. Sebastiani,et al. Gene expression in histologically normal epithelium from breast cancer patients and from cancer-free prophylactic mastectomy patients shares a similar profile , 2010, British Journal of Cancer.
[76] J. Burnett,et al. RNA-based therapeutics: current progress and future prospects. , 2012, Chemistry & biology.
[77] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumours , 2013 .
[78] S. Dhanasekaran,et al. The landscape of antisense gene expression in human cancers , 2015, Genome research.
[79] Masaru Tomita,et al. Comparative expression analysis uncovers novel features of endogenous antisense transcription. , 2008, Human molecular genetics.
[80] Clifford A. Meyer,et al. Gene expression profiling of human breast tissue samples using SAGE-Seq. , 2010, Genome research.
[81] Zoltan Szallasi,et al. Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer , 2010, Nature Medicine.
[82] H. Ditzel,et al. Identification of markers associated with highly aggressive metastatic phenotypes using quantitative comparative proteomics. , 2012, Cancer genomics & proteomics.
[83] Lars Juhl Jensen,et al. Cyclebase 3.0: a multi-organism database on cell-cycle regulation and phenotypes , 2014, Nucleic Acids Res..
[84] Thomas D. Wu,et al. Genetic Alterations and Oncogenic Pathways Associated with Breast Cancer Subtypes , 2009, Molecular Cancer Research.
[85] H. Kayed,et al. Expression of MAC30 protein is related to survival and biological variables in primary and metastatic colorectal cancers. , 2007, International journal of oncology.
[86] A. Weissman,et al. RING-dependent tumor suppression and G2/M arrest induced by the TRC8 hereditary kidney cancer gene , 2007, Oncogene.
[87] A. Protopopov,et al. Altered antisense-to-sense transcript ratios in breast cancer , 2010, Proceedings of the National Academy of Sciences.
[88] F. Montorsi,et al. Antisense transcription at the TRPM2 locus as a novel prognostic marker and therapeutic target in prostate cancer , 2014, Oncogene.
[89] Yitzhak Pilpel,et al. Genome‐wide natural antisense transcription: coupling its regulation to its different regulatory mechanisms , 2006, EMBO reports.
[90] R. Myers,et al. The ets-Related Transcription Factor GABP Directs Bidirectional Transcription , 2007, PLoS genetics.
[91] H. Tsukamura,et al. Single-stranded Noncoding RNAs Mediate Local Epigenetic Alterations at Gene Promoters in Rat Cell Lines* , 2011, The Journal of Biological Chemistry.
[92] Vladimir A. Kuznetsov,et al. Statistically Weighted Voting Analysis of Microarrays for Molecular Pattern Selection and Discovery Cancer Genotypes , 2006 .
[93] P. V. van Dam,et al. A phase II study of the combination of endocrine treatment and bortezomib in patients with endocrine-resistant metastatic breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[94] C. Wahlestedt. Natural antisense and noncoding RNA transcripts as potential drug targets. , 2006, Drug discovery today.
[95] D. Kang,et al. Genome-wide association study of childhood acute lymphoblastic leukemia in Korea. , 2010, Leukemia research.
[96] L. Greller,et al. Predicting Outcome in Follicular Lymphoma by Using Interactive Gene Pairs , 2008, Clinical Cancer Research.
[97] R. Roden,et al. Simultaneous inhibition of deubiquitinating enzymes (DUBs) and autophagy synergistically kills breast cancer cells , 2015, Oncotarget.
[98] G. Finocchiaro,et al. Localizing hotspots of antisense transcription , 2007, Nucleic acids research.
[99] Vladimir A. Kuznetsov,et al. Integrative analysis of the human cis-antisense gene pairs, miRNAs and their transcription regulation patterns , 2009, Nucleic acids research.
[100] T. Gingeras,et al. Genome-wide transcription and the implications for genomic organization , 2007, Nature Reviews Genetics.
[101] C. Méndez-Vidal,et al. Wrap53, a Natural p53 Antisense Transcript Required for p53 Induction upon DNA Damage. , 2016, Molecular cell.
[102] V. Devanarayan,et al. Human SPF45, a splicing factor, has limited expression in normal tissues, is overexpressed in many tumors, and can confer a multidrug-resistant phenotype to cells. , 2003, The American journal of pathology.
[103] Y. Xiong,et al. Vpr-Binding Protein Antagonizes p53-Mediated Transcription via Direct Interaction with H3 Tail , 2011, Molecular and Cellular Biology.
[104] Raja Jothi,et al. Critical Requirement of GABPα for Normal T Cell Development* , 2010, The Journal of Biological Chemistry.
[105] A. Ashworth,et al. An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers , 2010, Breast Cancer Research and Treatment.
[106] P. Baumann,et al. Telomerase RNA biogenesis involves sequential binding by Sm and Lsm complexes , 2012, Nature.
[107] C. Milcarek,et al. Expression of the thyroid hormone receptor gene, erbAalpha, in B lymphocytes: alternative mRNA processing is independent of differentiation but correlates with antisense RNA levels. , 1997, Nucleic acids research.
[108] Efthimios Motakis,et al. Complex sense-antisense architecture of TNFAIP1/POLDIP2 on 17q11.2 represents a novel transcriptional structural-functional gene module involved in breast cancer progression , 2010, BMC Genomics.
[109] Daniel Birnbaum,et al. A gene expression signature identifies two prognostic subgroups of basal breast cancer , 2011, Breast Cancer Research and Treatment.
[110] Xu Li,et al. Immunoscreening of urinary bladder cancer cDNA library and identification of potential tumor antigen , 2009, World Journal of Urology.
[111] M. Kurosumi,et al. The ubiquitin ligase CHIP acts as an upstream regulator of oncogenic pathways , 2009, Nature Cell Biology.
[112] Zhiyuan Shen,et al. BCCIP as a prognostic marker for radiotherapy of laryngeal cancer. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[113] S. Batalov,et al. Antisense Transcription in the Mammalian Transcriptome , 2005, Science.
[114] C. Ng,et al. Phase I clinical trials in 56 patients with thyroid cancer: the M. D. Anderson Cancer Center experience. , 2009, The Journal of clinical endocrinology and metabolism.
[115] Jeffrey T. Chang,et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies , 2006, Nature.
[116] Kerstin B. Meyer,et al. Master regulators of FGFR2 signalling and breast cancer risk , 2013, Nature Communications.
[117] L. Lipovich,et al. Sense-antisense gene pairs: sequence, transcription, and structure are not conserved between human and mouse , 2013, Front. Genet..
[118] M. Faghihi. Regulation of gene expression by non-protein-coding RNAs , 2009 .
[119] Heli Nevanlinna,et al. A genomic map of a 6-Mb region at 13q21-q22 implicated in cancer development: identification and characterization of candidate genes , 2002, Human Genetics.
[120] K. Nephew,et al. CHIP (carboxyl terminus of Hsc70-interacting protein) promotes basal and geldanamycin-induced degradation of estrogen receptor-alpha. , 2005, Molecular endocrinology.
[121] P. Rudnai,et al. SHMT1 1420 and MTHFR 677 variants are associated with rectal but not colon cancer , 2010, BMC Cancer.
[122] P. Potter,et al. The development and application of small molecule modulators of SF3b as therapeutic agents for cancer. , 2013, Drug discovery today.
[123] Audrey Kauffmann,et al. Bioinformatics Applications Note Arrayqualitymetrics—a Bioconductor Package for Quality Assessment of Microarray Data , 2022 .
[124] R. Greil,et al. A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[125] Thomas D. Schmittgen,et al. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.
[126] Renee Rubio,et al. Proliferative genes dominate malignancy-risk gene signature in histologically-normal breast tissue , 2009, Breast Cancer Research and Treatment.
[127] A. Børresen-Dale,et al. Identification of fusion genes in breast cancer by paired-end RNA-sequencing , 2011, Genome Biology.
[128] A. Nekrutenko,et al. Galaxy: a comprehensive approach for supporting accessible, reproducible, and transparent computational research in the life sciences , 2010, Genome Biology.
[129] T. Yokota,et al. GABPα regulates Oct-3/4 expression in mouse embryonic stem cells , 2007 .
[130] T. Morgan,et al. Expression of a noncoding RNA is elevated in Alzheimer's disease and drives rapid feed-forward regulation of β-secretase , 2008, Nature Medicine.
[131] Hailun Wang,et al. The PDZ protein TIP-1 facilitates cell migration and pulmonary metastasis of human invasive breast cancer cells in athymic mice. , 2012, Biochemical and biophysical research communications.
[132] Gavin R. Oliver,et al. Identification of differentially expressed sense and antisense transcript pairs in breast epithelial tissues , 2009, BMC Genomics.
[133] Yun Cui,et al. Bidirectional regulation between WDR83 and its natural antisense transcript DHPS in gastric cancer , 2012, Cell Research.
[134] Roland Somogyi,et al. Prediction of Graft-Versus-Host Disease in Humans by Donor Gene-Expression Profiling , 2007, PLoS medicine.
[135] Brad T. Sherman,et al. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists , 2008, Nucleic acids research.
[136] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumors , 2012, Nature.
[137] R. W. Williams,et al. Antisense transcription: A critical look in both directions , 2008, Cellular and Molecular Life Sciences.